查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2112890

2026-2034年全球病毒載體和質體DNA製造市場規模、佔有率、趨勢和成長分析報告

Global Viral Vector & Plasmid DNA Manufacturing Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 236 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球病毒載體和質體DNA生產市場預計將從2025年的69.7億美元成長至2034年的239.1億美元，2026年至2034年的複合年成長率（CAGR）為14.68%。基因治療、細胞治療和先進生物製藥的日益普及推動了全球病毒載體和質體DNA生產市場的快速擴張。慢病毒和腺病毒等病毒載體在基因編輯和免疫治療應用中遞送遺傳物質至關重要。 CAR-T療法和罕見疾病治療相關臨床試驗的激增顯著提高了對高品質載體和質體DNA生產能力的需求。

關鍵成長要素包括生物技術研發投入的增加、基因療法法規核准範圍的擴大，以及生物技術公司與合約研發生產機構（CDMO）之間合作的加強。可擴展生產平台和純化技術的進步正在提升生產效率。政府和私人投資者也在資助基礎設施建設，以緩解供應緊張並加速商業化。

隨著全球基因治療產品線的不斷擴展，市場預計將迎來強勁成長。從小小規模臨床生產向大規模商業化生產的轉變將創造巨大的商機。懸浮培養系統、自動化和閉迴路生產流程的創新可望提高產量並降低成本，從而支持病毒載體和質體DNA生產產業的長期發展。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球病毒載體與質體DNA生產市場：依載體類型分類

  • 市場分析、洞察與預測
  • 腺病毒
  • 逆轉錄病毒
  • 腺結合病毒（AAV）
  • 慢病毒
  • 質體
  • 其他

第5章 全球病毒載體與質體DNA生產市場：依工作流程分類

  • 市場分析、洞察與預測
  • 上游工程製造
  • 下游製造

第6章 全球病毒載體與質體DNA生產市場：依應用分類

  • 市場分析、洞察與預測
  • 反義和RNAi療法
  • 基因治療
  • 細胞療法
  • 疫苗學
  • 出於研究目的

第7章 全球病毒載體與質體DNA生產市場：依最終用途分類

  • 市場分析、洞察與預測
  • 製藥和生物製藥公司
  • 研究機構

第8章 全球病毒載體與質體DNA生產市場：依疾病分類

  • 市場分析、洞察與預測
  • 癌症
  • 遺傳性疾病
  • 感染疾病
  • 其他

第9章 全球病毒載體與質體DNA生產市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Thermo Fisher Scientific
    • Merck KGaA
    • Lonza
    • Fujifilm Diosynth Biotechnologies
    • Catalent Inc
    • Wuxi Biologics
    • Cobra Biologics
    • Takara Bio Inc
    • BioMarin Pharmaceutical
    • RegenxBioInc
    • Miltenyi Biotec GmbH
    • Sirion Biotech GmbH
    • Batavia Biosciences
    • Waisman Biomanufacturing
    • Genezen Laboratories
簡介目錄
Product Code: VMR11210492

The global viral vector & plasmid DNA manufacturing market size is expected to reach USD 23.91 Billion in 2034 from USD 6.97 Billion in 2025, growing at a CAGR of 14.68% during 2026-2034.The Global Viral Vector & Plasmid DNA Manufacturing Market has witnessed rapid expansion driven by the growing adoption of gene therapies, cell therapies, and advanced biologics. Viral vectors such as lentivirus and adenovirus are essential for delivering genetic material in gene editing and immunotherapy applications. The surge in clinical trials for CAR-T therapies and rare disease treatments has significantly increased demand for high-quality vector and plasmid DNA production capabilities.

Key growth drivers include rising investment in biotechnology research, increasing regulatory approvals for gene-based therapies, and expanding partnerships between biotech firms and contract development and manufacturing organizations (CDMOs). Technological advancements in scalable manufacturing platforms and improved purification techniques have enhanced production efficiency. Governments and private investors are also funding infrastructure development to address supply constraints and accelerate commercialization.

Looking ahead, the market is poised for strong growth as gene therapy pipelines continue to expand globally. The transition from small-scale clinical manufacturing to large-scale commercial production will create significant opportunities. Innovations in suspension cell culture systems, automation, and closed manufacturing processes are expected to improve yields and reduce costs, supporting long-term expansion of the viral vector and plasmid DNA manufacturing industry.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Vector Type

  • Adenovirus
  • Retrovirus
  • Adeno-Associated Virus (AAV)
  • Lentivirus
  • Plasmids
  • Others

By Workflow

  • Upstream Manufacturing
  • Downstream Manufacturing

By Application

  • Antisense & RNAi Therapy
  • Gene Therapy
  • Cell Therapy
  • Vaccinology
  • Research Applications

By End-use

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

By Disease

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others

COMPANIES PROFILED

  • Thermo Fisher Scientific, Merck KGaA, Lonza, Fujifilm Diosynth Biotechnologies, Catalent Inc., Wuxi Biologics, Cobra Biologics, Takara Bio Inc., BioMarin Pharmaceutical, RegenxBio, Inc., Miltenyi Biotec GmbH, Sirion Biotech GmbH, Batavia Biosciences, Waisman Biomanufacturing, Genezen Laboratories

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY VECTOR TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Vector Type
  • 4.2. Adenovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Retrovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Adeno-Associated Virus (AAV) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Lentivirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Plasmids Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY WORKFLOW 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Workflow
  • 5.2. Upstream Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Downstream Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Application
  • 6.2. Antisense & RNAi Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Vaccinology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Research Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY END-USE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End-use
  • 7.2. Pharmaceutical and Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY DISEASE 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Disease
  • 8.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Genetic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY REGION 2022-2034 (USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Vector Type
    • 9.2.2 By Workflow
    • 9.2.3 By Application
    • 9.2.4 By End-use
    • 9.2.5 By Disease
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Vector Type
    • 9.3.2 By Workflow
    • 9.3.3 By Application
    • 9.3.4 By End-use
    • 9.3.5 By Disease
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Vector Type
    • 9.4.2 By Workflow
    • 9.4.3 By Application
    • 9.4.4 By End-use
    • 9.4.5 By Disease
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Vector Type
    • 9.5.2 By Workflow
    • 9.5.3 By Application
    • 9.5.4 By End-use
    • 9.5.5 By Disease
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Vector Type
    • 9.6.2 By Workflow
    • 9.6.3 By Application
    • 9.6.4 By End-use
    • 9.6.5 By Disease
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Thermo Fisher Scientific
    • 11.2.2 Merck KGaA
    • 11.2.3 Lonza
    • 11.2.4 Fujifilm Diosynth Biotechnologies
    • 11.2.5 Catalent Inc
    • 11.2.6 Wuxi Biologics
    • 11.2.7 Cobra Biologics
    • 11.2.8 Takara Bio Inc
    • 11.2.9 BioMarin Pharmaceutical
    • 11.2.10 RegenxBioInc
    • 11.2.11 Miltenyi Biotec GmbH
    • 11.2.12 Sirion Biotech GmbH
    • 11.2.13 Batavia Biosciences
    • 11.2.14 Waisman Biomanufacturing
    • 11.2.15 Genezen Laboratories